Comprehensive Stock Comparison
Compare Adaptive Biotechnologies Corporation (ADPT) vs BiomX Inc. (PHGE) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  PHGE | Beta 0.93 vs ADPT's 1.31, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) |  ADPT | +104.7% vs PHGE's -48.8% |
| Efficiency (ROA) | ADPT | -16.2% ROA vs PHGE's -142.8%, ROIC -41.6% vs -305.2% |
Who Each Stock Is For
Income & stability
PHGEbeta 0.93
Growth exposure
PHGEEPS growth 71.2%
Long-term compounding (10Y)
ADPT-59.2% 10Y total return vs PHGE's -99.7%
Sleep-well-at-night portfolio
PHGELower volatility, beta 0.93, Low D/E 39.7%, current ratio 2.48x
Defensive / Recession hedge
PHGEBeta 0.93, current ratio 2.48x
Business Model
What each company does and how it makes money
Adaptive Biotechnologies is a biotechnology company that develops immune medicine platforms for diagnosing and treating diseases like cancer, autoimmune disorders, and infectious diseases. It generates revenue primarily through its clinical diagnostics segment — including its clonoSEQ test for minimal residual disease monitoring — and its translational and clinical genomics research services, with diagnostics contributing roughly 60% of revenue. The company's key advantage lies in its proprietary immune medicine platform that maps and translates the genetics of the adaptive immune system into clinical diagnostics and therapies.
BiomX is a clinical-stage biotechnology company developing targeted phage therapies — viruses that kill specific harmful bacteria — for chronic diseases and skin conditions. It generates no commercial revenue yet but is funded through equity offerings and partnerships to advance its pipeline, which includes therapies for cystic fibrosis, inflammatory bowel diseases, and atopic dermatitis. The company's key advantage is its proprietary platform for discovering and engineering natural phages that precisely target disease-causing bacteria while sparing beneficial microbes.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ADPT 4PHGE 0ADPT1/1 metricsADPT2/2 metricsADPT6/9 metricsADPT5/6 metricsADPT leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
ADPT and PHGE operate at a comparable scale, with $253M and $0 in trailing revenue.
| Metric | ADPTAdaptive Biotechn… | PHGEBiomX Inc. |
|---|---|---|
| RevenueTrailing 12 months | $253M | $0 |
| EBITDAEarnings before interest/tax | -$62M | -$6M |
| Net IncomeAfter-tax profit | -$80M | -$37M |
| Free Cash FlowCash after capex | -$63M | -$28M |
| Gross MarginGross profit ÷ Revenue | +71.8% | — |
| Operating MarginEBIT ÷ Revenue | -30.9% | — |
| Net MarginNet income ÷ Revenue | -31.5% | — |
| FCF MarginFCF ÷ Revenue | -24.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +102.4% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +126.6% | -6.5% |
Valuation Metrics
| Metric | ADPTAdaptive Biotechn… | PHGEBiomX Inc. |
|---|---|---|
| Market CapShares × price | $2.5B | $82.8B |
| Enterprise ValueMkt cap + debt − cash | $2.5B | $82.8B |
| Trailing P/EPrice ÷ TTM EPS | -15.22x | -4.29x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 14.02x | — |
| Price / BookPrice ÷ Book value/share | 11.94x | 3427.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ADPT delivers a -39.0% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-4 for PHGE. PHGE carries lower financial leverage with a 0.40x debt-to-equity ratio, signaling a more conservative balance sheet compared to ADPT's 0.44x. On the Piotroski fundamental quality scale (0–9), ADPT scores 4/9 vs PHGE's 3/9, reflecting mixed financial health.
| Metric | ADPTAdaptive Biotechn… | PHGEBiomX Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -39.0% | -3.6% |
| ROA (TTM)Return on assets | -16.2% | -142.8% |
| ROICReturn on invested capital | -41.6% | -3.1% |
| ROCEReturn on capital employed | -32.0% | -159.9% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.44x | 0.40x |
| Net DebtTotal debt minus cash | $41M | -$8M |
| Cash & Equiv.Liquid assets | $48M | $18M |
| Total DebtShort + long-term debt | $89M | $10M |
| Interest CoverageEBIT ÷ Interest expense | -6.25x | -36.86x |
Total Returns (with DRIP)
A $10,000 investment in ADPT five years ago would be worth $3,893 today (with dividends reinvested), compared to $47 for PHGE. Over the past 12 months, ADPT leads with a +104.7% total return vs PHGE's -48.8%. The 3-year compound annual growth rate (CAGR) favors ADPT at 24.8% vs PHGE's -59.1% — a key indicator of consistent wealth creation.
| Metric | ADPTAdaptive Biotechn… | PHGEBiomX Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +3.3% | +194.4% |
| 1-Year ReturnPast 12 months | +104.7% | -48.8% |
| 3-Year ReturnCumulative with dividends | +94.3% | -93.2% |
| 5-Year ReturnCumulative with dividends | -61.1% | -99.5% |
| 10-Year ReturnCumulative with dividends | -59.2% | -99.7% |
| CAGR (3Y)Annualised 3-year return | +24.8% | -59.1% |
Risk & Volatility
PHGE is the less volatile stock with a 0.93 beta — it tends to amplify market swings less than ADPT's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ADPT currently trades 79.2% from its 52-week high vs PHGE's 42.8% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADPTAdaptive Biotechn… | PHGEBiomX Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.93x |
| 52-Week HighHighest price in past year | $20.76 | $14.71 |
| 52-Week LowLowest price in past year | $6.26 | $1.56 |
| % of 52W HighCurrent price vs 52-week peak | +79.2% | +42.8% |
| RSI (14)Momentum oscillator 0–100 | 46.2 | 51.0 |
| Avg Volume (50D)Average daily shares traded | 1.8M | 1.3M |
Analyst Outlook
| Metric | ADPTAdaptive Biotechn… | PHGEBiomX Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $21.25 | — |
| # AnalystsCovering analysts | 17 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Adaptive Biotechnol… (ADPT) | 100 | 58.58 | -41.4% |
| BiomX Inc. (PHGE) | 100 | 0.23 | -99.8% |
Adaptive Biotechnol… (ADPT) returned -61% over 5 years vs BiomX Inc. (PHGE)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| Adaptive Biotechnol… (ADPT) | $38M | $179M | +365.5% |
| BiomX Inc. (PHGE) | $0.00 | $0.00 | — |
Adaptive Biotechnologies Corporation's revenue grew from $38M (2017) to $179M (2024) — a 24.6% CAGR. BiomX Inc.'s revenue grew from $0M (2017) to $0M (2024) — a 0.0% CAGR.
Chart 3EPS Growth — 10 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| Adaptive Biotechnol… (ADPT) | -0.41 | -1.08 | -163.4% |
| BiomX Inc. (PHGE) | -3.27 | -1.47 | +55.0% |
Adaptive Biotechnologies Corporation's EPS grew from $-0.41 (2017) to $-1.08 (2024). BiomX Inc.'s EPS grew from $-3.27 (2017) to $-1.47 (2024).
Chart 4Free Cash Flow — 5 Years
Adaptive Biotechnologies Corporation generated $-99M FCF in 2024 (+61% vs 2021). BiomX Inc. generated $-37M FCF in 2024 (-18% vs 2021).
ADPT vs PHGE: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ADPT or PHGE a better buy right now?
Analysts rate Adaptive Biotechnologies Corporation (ADPT) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ADPT or PHGE?
Over the past 5 years, Adaptive Biotechnologies Corporation (ADPT) delivered a total return of -61.1%, compared to -99.5% for BiomX Inc. (PHGE). A $10,000 investment in ADPT five years ago would be worth approximately $4K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADPT returned -59.2% versus PHGE's -99.7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ADPT or PHGE?
By beta (market sensitivity over 5 years), BiomX Inc. (PHGE) is the lower-risk stock at 0.93β versus Adaptive Biotechnologies Corporation's 1.31β — meaning ADPT is approximately 42% more volatile than PHGE relative to the S&P 500. On balance sheet safety, BiomX Inc. (PHGE) carries a lower debt/equity ratio of 40% versus 44% for Adaptive Biotechnologies Corporation — giving it more financial flexibility in a downturn.
04Which has better profit margins — ADPT or PHGE?
BiomX Inc. (PHGE) is the more profitable company, earning 0.0% net margin versus -89.1% for Adaptive Biotechnologies Corporation — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PHGE leads at 0.0% versus -90.8% for ADPT. At the gross margin level — before operating expenses — ADPT leads at 59.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ADPT or PHGE?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ADPT or PHGE better for a retirement portfolio?
For long-horizon retirement investors, BiomX Inc. (PHGE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.93)). Both have compounded well over 10 years (PHGE: -99.7%, ADPT: -59.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ADPT and PHGE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.